[go: up one dir, main page]

TNSN08512A1 - Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists - Google Patents

Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Info

Publication number
TNSN08512A1
TNSN08512A1 TNP2008000512A TNSN08512A TNSN08512A1 TN SN08512 A1 TNSN08512 A1 TN SN08512A1 TN P2008000512 A TNP2008000512 A TN P2008000512A TN SN08512 A TNSN08512 A TN SN08512A TN SN08512 A1 TNSN08512 A1 TN SN08512A1
Authority
TN
Tunisia
Prior art keywords
tumors
treatment
growth factor
receptor antagonists
factor receptor
Prior art date
Application number
TNP2008000512A
Other languages
English (en)
Inventor
Eric Rowinsky
Original Assignee
Imclone Systems Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Incorporated filed Critical Imclone Systems Incorporated
Publication of TNSN08512A1 publication Critical patent/TNSN08512A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2008000512A 2006-07-27 2008-12-11 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists TNSN08512A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83348706P 2006-07-27 2006-07-27
PCT/US2007/074448 WO2008014386A2 (fr) 2006-07-27 2007-07-26 Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique

Publications (1)

Publication Number Publication Date
TNSN08512A1 true TNSN08512A1 (en) 2010-04-14

Family

ID=38982334

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000512A TNSN08512A1 (en) 2006-07-27 2008-12-11 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Country Status (15)

Country Link
EP (1) EP2043688A4 (fr)
JP (1) JP2009544736A (fr)
KR (1) KR20090033841A (fr)
CN (1) CN101484186A (fr)
AU (1) AU2007279261A1 (fr)
BR (1) BRPI0712368A2 (fr)
CA (1) CA2654911A1 (fr)
CR (1) CR10486A (fr)
EA (1) EA200870603A1 (fr)
EC (1) ECSP089011A (fr)
MX (1) MX2008016187A (fr)
NO (1) NO20085182L (fr)
TN (1) TNSN08512A1 (fr)
WO (1) WO2008014386A2 (fr)
ZA (1) ZA200810600B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202192413A1 (ru) * 2019-03-27 2021-12-30 Нэшнл Рисеч Каунсил Оф Канада АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ

Also Published As

Publication number Publication date
CR10486A (es) 2009-02-23
ECSP089011A (es) 2009-01-30
JP2009544736A (ja) 2009-12-17
MX2008016187A (es) 2009-01-20
CA2654911A1 (fr) 2008-01-30
KR20090033841A (ko) 2009-04-06
BRPI0712368A2 (pt) 2012-06-05
ZA200810600B (en) 2009-11-25
CN101484186A (zh) 2009-07-15
EA200870603A1 (ru) 2009-06-30
WO2008014386A2 (fr) 2008-01-31
EP2043688A4 (fr) 2009-11-11
AU2007279261A1 (en) 2008-01-31
EP2043688A2 (fr) 2009-04-08
WO2008014386A3 (fr) 2008-07-03
NO20085182L (no) 2009-04-24

Similar Documents

Publication Publication Date Title
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
EP2046973A4 (fr) Procédés d'identification, d'évaluation, et de traitement de patients soumis à une thérapie anticancéreuse
IN2014DN11099A (fr)
NZ598145A (en) Folate-targeted diagnostics and treatment
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
IL205960A0 (en) Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
SG170752A1 (en) Benzimidazoles which have activity at m1 receptor and their uses in medicine
WO2011009020A3 (fr) Composés et compositions pour une utilisation en photothérapie et dans le traitement d'une maladie néovasculaire oculaire et de cancers
WO2009137543A3 (fr) Procédés pour le dépistage et le traitement du cancer du sein
MY161288A (en) Combination anti - cancer therapy
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2008060899A3 (fr) Procédés de dépistage et de traitement du cancer du sein
TW200630089A (en) Treatment methods
EP1781296A4 (fr) Derives de quinazoline, utilisation de ces derniers dans le traitement de la thrombocythemie
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
TNSN08512A1 (en) Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists
WO2008039525A3 (fr) Procédés de traitement du cancer au moyen d'antagonistes de cadhérine combinés à des agents anticancéreux
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
DE602005026510D1 (en) Anthracyclinderivate
ZA200904571B (en) VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
HK1131409A (en) For the identification, assessment, and treatment of patients with cancer therapy